Adult T-cell leukemia/lymphoma (ATLL) develops after infection with human T-cell leukemia virus-1 (HTLV-1) after a long latency period. The negative regulatory programmed death-1/ programmed death-1 ligand 1 (PD-1/PD-L1) pathway has been implicated in the induction of cytotoxic T-lymphocyte (CTL) exhaustion during chronic viral infection along with tumor escape from host immunity. To determine whether the PD-1/ PD-L1 pathway could be involved in the establishment of persistent HTLV-1 infections and immune evasion of ATLL cells in patients, we examined PD-1/PD-L1 expression on cells from 27 asymptomatic HTLV-1 carriers (ACs) and 27 ATLL patients in comparison with cells from 18 healthy donors. PD-1 expression on HTLV-1-specific CTLs from ACs and ATLL patients was dramatically elevated. In addition, PD-1 expression was significantly higher on CD8 þ T cells along with cytomegalovirus (CMV)-and Epstein-Barr virus (EBV)-specific CTLs in ATLL patients compared with ACs and control individuals. Primary ATLL cells in 21.7% of ATLL patients expressed PD-L1, whereas elevated expression was not observed in cells from ACs. Finally, in functional studies, we observed that an anti-PD-L1 antagonistic antibody upregulated HTLV-1-specific CD8 þ T-cell response. These observations suggest that the PD-1/ PD-L1 pathway plays a role in fostering persistent HTLV-1 infections, which may further ATLL development and facilitate immune evasion by ATLL cells.
Introduction
Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive peripheral T-cell neoplasm that develops only after long-term chronic infections with human T-cell leukemia virus-1 (HTLV-1). [1] [2] [3] [4] Despite recent progress in both chemotherapy and supportive care for hematological malignancies, the prognosis of ATLL is still poor; overall survival at 3 years is only 24%. [5] [6] [7] [8] Human T-cell leukemia virus-1 is a human retrovirus that has infected approximately 10-20 million people worldwide, particularly in southern Japan, the Caribbean Basin, South America, Melanesia and Equatorial Africa. 9 Despite this high frequency of human infection, only 2-5% of HTLV-1-infected individuals develop ATLL. 7, 10 Multiple factors (for example, virus, host cell and immune factors) have been implicated in the development of ATLL, although the underlying mechanisms of leukemogenesis have not been fully elucidated. 5, 8, 10 Recently, lines of evidence suggest that HTLV-1-specific cytotoxic T lymphocytes (CTLs) play an important role in suppressing the proliferation of HTLV-1-infected or transformed T cells, and thus may prevent the development of ATLL. 11, 12 We have also reported on the reduced frequency and function of HTLV-1 Tax-specific CD8 þ T cells in ATLL patients. 13 Taken together, it is thus of great interest to further explore the role of the host T-cell immune system in understanding the persistence of HTLV-1 infections and ATLL leukemogenesis.
The T-cell receptor costimulatory pathways assist in regulating T-cell activation and tolerance. [14] [15] [16] The B7-CD28 superfamily membership has been expanded to include costimulatory and inhibitory T-cell receptors, including CD28 and programmed death-1 (PD-1). 15, 17 Indeed, studies in PD-1-deficient mice have indicated that PD-1 serves as a negative regulator of immune responses. 18 PD-1 signaling is involved in autoimmunity, allergy, sites of immune privilege and antitumor immunity.
14, 16 The interaction of PD-1 with the ligand, programmed death-1 ligand 1 (PD-L1), has been reported to negatively regulate the cytokine production and proliferation of T cells. 14, 19, 20 Interestingly, PD-L1 expression is also associated with poor prognosis in many cancers, including those of the larynx, lung, stomach, colon, breast, cervix, ovary, renal cell, bladder and liver, as well as in glioma and melanoma.
14 Further, it has been suggested that such tumors may actually evade the host immune system by attenuation of tumor-specific T-cell responses through the PD-1/PD-L1 pathway. [21] [22] [23] In addition, PD-1 has recently been shown to be involved in chronic viral infections. For example, Barber et al. 24 reported that PD-1 is upregulated in T cells that become exhausted during the chronic phase of viral infection in lymphocytic choriomeningitis virus infected mice. Moreover, blocking the interaction between PD-1 and PD-L1 reactivates the CTL function in those mice. 24 Studies have also suggested that the PD-1/PD-L1 pathway in virus-specific CD8 þ T cells may be operating in chronic HIV infection. [25] [26] [27] However, there is no report on PD-1 expression in tumor-associated antigen-specific CTLs in humans. Therefore, it is important to explore the association between the PD-1/ PD-L1 pathway and HTLV-1 infection, in terms of both maintenance of the chronic infection and possible effects on the host immune system in this virus-induced malignancy in humans.
In this study, we examined the expression and interaction of PD-1/PD-L1 in asymptomatic HTLV-1 carriers (ACs), ATLL patients and non-HTLV-1-infected individuals to investigate the role of this negative regulatory axis in chronic HTLV-1 infection and associated leukemia.
Materials and methods

Patients
The patients in this study included 27 ACs (24-81 years of age, mean ¼ 59.3), 27 ATLL patients (31-83 years of age, mean ¼ 62.2; two with chronic type, three with lymphoma type and 22 with acute type) and 18 non-HTLV-1-infected healthy donors (HDs; 23-57 years of age, mean ¼ 34.9), all of whom were recruited from the Kagoshima University Hospital. Patients were examined by a standard serological testing for the presence of HTLV-1 and by hematological/Southern blotting analysis for the diagnosis of ATLL. Those patients seropositive for HTLV-1 without clinical symptoms of HTLV-1-related diseases 28 were designated as ACs. Classification of ATLL was made according to Shimoyama's criteria. 29 All patients were inhabitants of Kagoshima prefecture, southern Kyushu and Japan, where ATLL is endemic. All patients gave their written informed consent to participate in this study and to allow review of their medical records, and they also provided a sample of peripheral blood for human leukocyte antigen (HLA) typing and for the HLA tetramer assay. The study protocol was reviewed and approved by the Medical Ethical Committee of Kagoshima University.
Phenotypic analysis
Cells from patients positive for HLA-A * 24 were screened by serological staining with monoclonal antibodies (mAbs) for HLA-A*24 subtypes (clone: 17A10; Medical and Biological Laboratories, Nagoya, Japan), followed by secondary staining with goat anti-mouse IgG-fluorescein isothiocyanate (FITC) (Immunotech, Miami, FL, USA) according to the manufacturer's instructions, and subjected to flow cytometry analyses on FACScan (Becton Dickinson, Mountain View, CA, USA). Phenotypic analysis using HLA tetramers was performed as described earlier. 13 Briefly, aliquots of 1 Â 10 6 freshly isolated peripheral blood mononuclear cells (PBMCs) were incubated with the HLA tetramers, FITC-conjugated murine anti-PD-1 mAbs (clone: MIH4; eBioscience, San Diego, CA, USA) and peridinin chlorophyll-a protein-conjugated murine anti-CD8 mAbs (Becton Dickinson, San Jose, CA, USA). Lymphocytes, CD8 þ lymphocytes and tetramer-positive CD8 þ lymphocytes were analyzed using the FACScan instrument (Becton Dickinson) 30 and FlowJo software (Tree Star, San Carlos, CA, USA). 31 HTLV-1 Tax/HLA tetramers; Tax 301-309 (SFHFLHLLF) with HLA-A * 2402 were used in this study (Beckman Coulter Co., Fullerton, CA, USA). Phycoerythrin (PE)-labeled HLA tetramers were produced as described earlier. 32, 33 Staining was also performed with an HIV (RYLRDQQLL)/HLA-An2402 tetramer (Medical and Biological Laboratories) as a negative control, a cytomegalovirus (CMV) (QYDPVAALF)/HLA-An2402 tetramer and an Epstein-Barr virus (EBV) BRLF1(TYPVLEEMF)/ HLA-A * 2402 tetramer (Beckman Coulter). 13 We estimated the surface PD-1 expression by subtracting the percentage of isotype control-positive cells from the percentage of anti-PD-1-positive cells. Aliquots of 1 Â 10 6 PBMCs were stained with an FITCconjugated murine anti-CD25 mAb (Beckman Coulter), a PE-conjugated murine anti-CD4 mAb (Beckman Coulter), a Cy7-conjugated murine anti-PD-L1 mAbs (clone: MIH1; eBioscience) or an isotype control mouse IgG1 antibody (eBioscience). We estimated the surface PD-L1 expression by subtracting the percentage of isotype control-positive cells from the percentage of anti-PD-1-positive cells.
Intracellular Tax, IFN-g and TNF-a staining assay
Peripheral blood mononuclear cells (1 Â 10 6 ) for HTLV-1 Tax expression analysis were cultured for 12 h in complete medium (CM; RPMI-1640 supplemented with the following reagents: 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.05 mM 2-mercaptoethanol, 50 U/ml of recombinant human interleukin-2 and 10% heat-inactivated FCS). PBMCs were labeled with Cy7-conjugated murine anti-PD-L1 mAbs, anti-CD4-PE and anti-CD25-allophycocyanin antibody (Becton Dickinson) for cell-surface antigen analyses. 34 PBMCs (1 Â 10
6
) for interferon-g (IFN-g) and tumor necrosis factor-a (TNF-a) analyses were cultured for 16 h with or without 0.02 mM HTLV-1 Tax peptide (Sigma Aldrich, Tokyo, Japan) in combination with brefeldin A (Becton Dickinson) in CM. Blocking antibody specific to PD-L1 (clone: MIH1; eBioscience) was added to cell cultures at a concentration of 10 mg/ml. 21, 35, 36 Cells were collected and labeled with HTLV-1/HLA-tetramer-PE and anti-CD8-allophycocyanin antibodies (Becton Dickinson). 34 These cells were further treated with permeabilizing solution (Becton Dickinson). After washing, the cells were incubated with antiTax-FITC (clone: Lt4; kindly provided by Tanaka Y, Ryukyu University), IFN-g-FITC or TNF-a-FITC antibody (Becton Dickinson). As a negative control, staining was also performed with isotype control IgG1-FITC (Becton Dickinson) for Tax and FastImmune Control g2aFITC/g1PE for IFN-g and TNF-a (Becton Dickinson). Lymphocyte analyses were performed using FACSCalibur and analyzed with FlowJo software.
13
CD107a mobilization assay
Assessment of cytolytic ability was performed using flow cytometric quantification of the surface mobilization of CD107aFan integral membrane protein in cytolytic granulesFas a marker of degranulation after stimulation, as described earlier. 13, 37 Briefly, PBMCs (1 Â 10 6
) were cultured for 6 h with or without 0.02 mM HTLV-1 Tax peptide (Sigma Aldrich) in combination with anti-CD107a mAbs-FITC (clone: H4A3; Southern Biotech, Birmingham, AL, USA) and the secretion inhibitor monensin (Becton Dickinson) in CM. Blocking antibody specific to PD-L1 (clone: MIH1; eBioscience) was added to cell cultures at a concentration of 10 mg/ml. The cells were further stained with HLA-tetramer-PE and anti-CD8 mAb-PE/Cy5 (Beckman Coulter) as described earlier. 13 Aliquots of 1 Â 10 4 CD8 þ T lymphocytes were examined using FACSCalibur and analyzed with FlowJo software.
Statistical analysis
Mann-Whitney-and Wilcoxon-matched pair tests were performed using a StatView software version 5.0 (SAS Institute Inc., Cary, NC, USA). P-values of less than 0.05 were considered significant.
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Results
PD-1 expression in ACs and ATLL patients
Freshly isolated or cryopreserved PBMCs from 27 ACs and 25 ATLL patients were stained for PD-1 in combination with CD8 and HTLV-1 Tax, CMV or EBV tetramers, allowing for the direct visualization of PD-1 expression on tetramerpositive CD8 þ lymphocytes. In this study, the cell-surface phenotype of ATLL cells determined by flow cytometric analyses showed the CD4 þ /CD25 þ /CD8 À (data not shown). We were able to exclude the contribution of PD-1 expression from ATLL cells by analyzing PD-1 expression on CD8 þ cells. PD-1 expression was readily apparent on lymphocytes and tetramer-positive CD8 þ T cells (Figure 1 ). Percentages of total and CD8 þ lymphocytes from ACs and ATLL patients expressing PD-1 were significantly higher than those from HDs (Figure 1b , Po0.01 and 0.001, respectively). Importantly, percentages of total and CD8 þ lymphocytes in ATLL patients who expressed PD-1 were significantly even higher than those from ACs (Po0.01). Overall, there was no correlation between age and the rates of PD-1 expression, although ATLL patients with high PD-1 expression were significantly younger than those with low PD-1 expression (58.1 years of age versus 67.3 years of age, Po0.05, data not shown).
We next assessed PD-1 expression on viral antigen-specific CD8 þ lymphocytes (Figure 1c) . The rates of PD-1 expression on CMV-and EBV-tetramer-positive CD8 þ lymphocytes from ATLL patients were significantly higher than those in HDs (Figure 1c , Po0.01 and 0.005, respectively) and ACs (Po0.01 and 0.05, respectively). In contrast, we found that 72.7±27.1% of HTLV-1-tetramer-positive CD8 þ lymphocytes from ACs expressed PD-1 and that a similar number of HTLV-1-tetramer-positive lymphocytes from ATLL patients expressed PD-1 (P ¼ 0.32). Furthermore, PD-1 was expressed on significantly higher percentages of HTLV-1-specific cells as compared with CMV-and EBV-specific CD8 þ T cells in ACs (Po0.01 and 0.05, respectively), but not in ATLL patients. These observations regarding PD-1 cell-surface expression were unique as we did not observe simultaneous increased cell-surface expression of the inhibitory receptor CTL antigen-4 (data not shown).
PD-L1 expression in ACs and ATLL patients
To explore whether ATLL cells and HTLV-1-infected cells could possibly evade the host immune system by expression of the Figure 2b along with the percentage of abnormal lymphocytes in peripheral blood. There was no correlation between the percentage of PD-L1 expression on CD4 þ CD25 cells and the percentage of abnormal lymphocytes in peripheral blood. Lymphocytes from ACs were negative for PD-L1 expression (mean ¼ 0.3 ± 0.57%, data not shown), whereas 5 of 23 ATLL patients (21.7%) showed higher rates of PD-L1 expression on lymphocytes (mean ¼ 11.6 ± 27.8%, Figure 2b ). Among HDs, the percentage of lymphocytes expressing PD-L1 was 0.43 ± 0.62 (data not shown). PD-L1 expression on the CD4 þ CD25 lymphocytes appeared to vary among individuals. Such variation is also seen in vitro; the cloned HTLV-1-infected Oh13T cell line and HTLV-1-negative Jurkat cell line expressed PD-L1, whereas HTLV-1-infected Su9TO1, K3T, F6T, SlT 38 and HTLV-1-negative MOLT-4 and KG-1 had no measurable PD-L1 expression (data not shown). The percentage of PD-L1 expression on CD4 þ CD25 þ cells was summarized in Figure 2c along with the percentage of PD-1 expression in CD8 þ lymphocytes. There was no correlation between the percentage of PD-L1 expression on CD4 þ CD25 cells and the percentage of PD-1 expression in CD8 þ lymphocytes. We compared the clinical characteristics of two groups of ATLL cases, in which one group showed high expression and the other showed low expression of PD-L1 on ATLL cells. There are no differences between those groups in terms of chemosensitivity, survival, hypercalcemia, LDH, percentage of ATLL cells in peripheral blood and involvement of other organs. However, PD-L1 expression was not observed in the CD4 þ CD25 þ cells at diagnosis in all ATLL patients. Samples from all the five patients who express high PD-L1 on CD4 þ CD25 þ cells (410%) were collected at least 12 months after diagnosis (21.0±15.3 months). Three of the five patients were severely refractory to chemotherapy, and the other two patients were in chronic stage.
To explore whether PD-L1 expression occurs on HTLV-1-infected cells, we examined T cells expressing Tax, an HTLV-1 oncoprotein. PD-L1 expression was observed on PBMCs cultured for 12 h from ACs (6 of 7), but not from HDs (0 of 6, representative data shown in Figure 3) . Overall, 84.7% of the HTLV-1 Tax þ cultured cells expressed PD-L1, although there was no HTLV-1 Tax expression on cells freshly isolated from ACs. Interestingly, all HTLV-1 Tax þ PD-L1 þ lymphocytes were CD4 þ CD25 þ (data not shown). Thus, HTLV-1-infected cells were conditionally capable of inducing PD-L1 expression.
Blockade of the PD-1/PD-L1 pathway enhances CD8 þ T-cell function
To assess whether PD-1 expression on CD8 þ lymphocytes from ACs and ATLL patients could affect function, cytolytic reactions were performed using flow cytometric quantification of intracellular IFN-g and TNF-a produced in HTLV-1 Tax-specific CD8 þ cells. These cytokines are primarily produced by activated lymphocytes and act as multifunctional immunomodulators with antitumor and antiviral activity. 31 Representative results regarding IFN-g, TNF-a and CD107a production are 
Discussion
A higher percentage of PD-1 expression was observed on total and CD8 þ T cells in ACs compared with HDs ( Figure 1b) . Although no earlier study of other oncogenic viruses has shown a correlation between PD-1 expression and the carrier state or eventual progression to cancer, in this study, we report that the percentage of CD8 þ lymphocytes expressing PD-1 was higher for ATLL patients compared with ACs ( Figure 1b) . Even though we failed to measure HTLV-I provirus load with those samples, this may reflect the higher load of virus-associated antigens in ATLL patients than in ACs, as it has also been shown that the PD-1 expression is increased in HIV viremic compared with aviremic individuals. 27 Indeed, our Tax data here (Figure 3 ) indicate that there may be some correlation between these effects. The observation of fairly high rates of PD-1 expression on CD8 þ lymphocytes in ATLL patients and ACs compared with HDs prompted us to investigate PD-1 expression on viral antigen-specific CTL from ATLL patients, ACs and HDs. PD-1 expression on HTLV-1-specific CD8 þ lymphocytes from ACs was just as high as that observed on cells from ATLL patients, whereas PD-1 expression on CMV-and EBV-tetramer-positive CD8 þ lymphocytes was also upregulated, but to a lesser extent than on cells from in ATLL patients (Figure 1c ). These observations suggest relatively skewed exhaustion of CTLs against HTLV-1 more than against other viruses in the carrier state, which is consistent with the observation that ATLL patients show a broadly compromised immune system. 11, 39 This may be The interaction of PD-1 with PD-L1 has been shown to negatively regulate the cytokine production and proliferation of T cells, allowing tumor evasion of the host immune system by negative attenuation of tumor-specific T-cell responses. 19, 23 PD-L1 expression is found on many solid tumors, and increased expression of PD-L1 is associated with poor prognosis. 19, 22, 41 In this study, we showed that some primary ATLL cells express PD-L1 on the cell surface ( Figure 2) ; however, the expression patterns varied considerably between individual patients. Notably, none of the ATLL patients expressed PD-L1 at diagnosis on ATLL cells in this cohort. Samples from all five patients who express high PD-L1 on CD4 þ CD25 þ cells (410%) were collected at least 12 months after diagnosis. Shimauchi et al. 42 also reported that CD4 þ CD25 þ tumor cells expressed a low but discernible level of PD-L1 in only one of four cases. This and our data are in contrast with an earlier study that assessed PD-L1 expression in 30 heterogenous acute leukemia patients and found that 57% of patients expressed PD-L1 at diagnosis on leukemic cells. 43 The serial measurement of PD-L1 expression on ATLL cells clearly needs to be carried out to determine the significance of PD-L1 expression for the disease characteristics.
Nakanishi et al. 44 reported increased PD-1 expression on tumor-infiltrating lymphocytes; however, the specificity of tumor-infiltrating lymphocytes against tumor-associated antigens was not addressed because of technical limitations. In our study, we assessed CTL specific to HTLV-1, which is a tumorcausing virus, using a well-established and highly sensitive tetramer assay. This may provide direct evidence that the PD-1/ PD-L1 interaction is one of the mechanisms allowing ATLL evasion from the host immune system. Although approximately 60% of ATLL cells do not express Tax protein in vivo, 7 it has been reported that HTLV-1 Tax-specific CD8 þ lymphocytes play an important role in ATLL tumor immunity after hematopoietic stem cell transplantation. 12 This tumor-associated antigen-specific tetramer assay will be used further to assess whether therapeutic intervention against the PD-1/PD-L1 pathway can restore PD-1-expressing CD8 þ lymphocytes in a malignancy setting, as has been reported in chronic viral infection models. 25 Although some ATLL cells from uncultured peripheral blood did not express PD-L1, we found that HTLV-1-infected cells are capable of producing PD-L1 in short-term PD-1/PD-L1 expression in HTLV-1 carriers and ATLL T Kozako et al culture assays (Figure 3) . PD-1 expression in HTLV-1-specific CD8 þ T cells in ACs and ATLL patients is similarly increased. These results suggest that interaction of high PD-1 expression on HTLV-1-specific CD8 þ T cells could occur with PD-L1 in ATLL patients. Indeed, an earlier study has shown that PD-L1 is upregulated in HIV-infected individuals; 26 yet, to date, it is unknown whether HIV-infected cells that express viral-derived protein are capable of producing PD-L1.
Our earlier study revealed that HTLV-1-specific CD8 þ T cells, which produce intracellular molecules relevant to cytolytic effector function (IFN-g, perforin and granzyme B) , are lacking in effector functions in ATLL patients. 13 Here, we also examined whether interrupting the ligation of PD-1 by its ligand PD-L1 could increase the cytolytic potential of HTLV-1-specific CD8 þ T cells, similar to reports in a mouse model in vivo using cells from glioma and HIV patients in vitro. 24, 25, 27, 41 Our results showed that blockade of the PD-1/ PD-L1 pathway augmented the production of IFN-g, TNF-a and expression of the degranulation marker, CD107a, by effector cells. Blank et al. 21 also reported that blockade of endogenous PD-L1 expression on human cancer cells can still improve the immune functions of tumor-specific T cells in vitro. Furthermore, Maier et al. 45 reported that blockade of PD-1/PD-L1 pathways may reverse viral persistence and chronic infection in cases, in which the CTL secretion of IFN-g, after antigen recognition in the liver is suppressed. Taken together, the results of these studies suggest that an effective blockade of PD-L1 interactions with immune effector cells in vivo may provide a promising strategy of immunotherapy for selected tumors expressing PD-L1. 14, 21, 23 In summary, this study indicates that the immunoregulatory PD-1/PD-L1 pathway is operative during persistent viral infection, and suggests that this pathway may contribute to exhaustion of the CTL response in HTLV-1-infected individuals, which may facilitate immune evasion and ATLL development. Furthermore, interventions that lead to reactivation of exhausted T cells by blocking the PD-1/PD-L1 axis may be an effective immunological strategy for the clearance of persistent HTLV-1 infection and the treatment of ATLL.
